SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Hepatitis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI5/28/2006 2:06:04 AM
   of 312
 
Recommended (portion of) webcast on HCV therapy:

corporate-ir.net [click on the first webcast link—the one from DDW on 5/23/06]

The part of the webcast to hear is the first third (about 25 minutes), which is an overview of the state of current HCV therapy by Dr. Myron Tong, Chief of the Liver Center of Huntington Medical Research Institute in Pasadena, CA.

(The middle third of the webcast is a rather pedestrian description of the desired properties of future HCV therapies, and the final third is a discussion of ITMN’s protease inhibitor, which I found less interesting because it was about cell-line assays rather than clinical results.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News